Xeljanz is a drug made by Pfizer to treat moderate to severe rheumatoid arthritis inflammation. The drug, first approved in 2012, works by blocking certain enzymes and suppressing a user’s immune system. An “extended release” form of the drug, Xeljanz XR was approved for treatment of active psoriatic arthritis in 2017. Pfizer made about $1.7 billion off Xeljanz and Xeljanz XR in 2018 alone.
Last February the U.S. Food & Drug Administration issued a warning about an increased risk of developing a Pulmonary Embolism in Xeljanz users – preliminary results from ongoing clinical studies indicated individuals taking 10mg of Xeljanz twice a day 3 to 5 times more likely to develop a blood clot in the lungs compared to individuals using alternative arthritis medications. Between 2013 and 2018, the FDA received over 40,000 adverse event reports concerning Xeljanz and Xeljanz XR, almost 1,000 of which were deaths.
A pulmonary embolism is a life-threatening condition that occurs when a blood clot occurs in an artery in the lungs. The condition constitutes a medical emergency that requires immediate treatment. A blood clot in the lung restricts blood flow and decreases oxygen levels which can permanently damage the lungs and other organs. Such a blockage can be fatal.Even Pfizer has confirmed that Xeljanz users have a significantly higher risk of developing blood clots than other comparable drugs.
If you or a loved one were prescribed 10mg doses of Xeljanz or Xeljanz XR twice a day for rheumatoid or psoriatic arthritis and suffered a stroke, Pulmonary Embolism or died, contact us online or call us at 1-866-252-3535.
Do not stop taking any medication without consulting your healthcare provider.